TOP TEN perturbations for 39077_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39077_at
Selected probe(set): 227963_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39077_at (227963_at) across 6674 perturbations tested by GENEVESTIGATOR:
H14 BJI / H14.s3
Relative Expression (log2-ratio):5.6449423Number of Samples:2 / 2
| Experimental | H14 BJI |
| Human embryonic stem cells H14 BJI with abnormal karyotype, including a homogenous staining region (48,XY,+12,+der(17)del(17)(p12p13.3)hsr(17)(p11.2)). Synonyms:H14 BJI; H14BJ1; H14.BJ1 Parental cell line:: WA14 Cellosaurus code: | |
| Control | H14.s3 |
| Human embryonic stem cells H14.s3 with normal male karyotype. Parental cell line:: WA14 |
CAR T cell study 4 (PSCA-28t28Z; post-infusion) / CAR T cell study 4 (PSCA-28t28Z; pre-infusion)
Relative Expression (log2-ratio):-3.6624813Number of Samples:3 / 3
| Experimental | CAR T cell study 4 (PSCA-28t28Z; post-infusion) |
| CD8+ T cells transduced with PSCA-28t28Z (second generation CAR) and isolated 30 days after adoptive transfer into mice bearing HPAC-derived pancreatic tumor. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-28t28Z. Cells were cultured for 2 weeks in presence of IL-2 and then transfered into 4-5-week-old male NSG mice. Subcutaneous xenografts were generated by injection of HPAC cells. Once tumors became palpable, mice were treated with CD8+ T cells expressing PSCA-28t28Z. Untransduced CD4+ cells from the same donor were given to each mouse for cytokine support. Spleen-resident human CD8+ T cells were isolated 30 days later using the CD8 MicroBeads (post-infusion samples). | |
| Control | CAR T cell study 4 (PSCA-28t28Z; pre-infusion) |
| Primary human CD8+ T cells stimulated ex vivo and transduced to express PSCA-28t28Z (second generation CAR). Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-28t28Z. Cells were cultured for 2 weeks in presence of IL-2, until collection of samples (pre-infusion samples). |
bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary) / bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)
Relative Expression (log2-ratio):3.5549555Number of Samples:2 / 2
| Experimental | bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary chondroblastic osteosarcoma of the bone (subcutaneously implanted). | |
| Control | bone cancer study 1 (PDX; myxoid chondrosarcoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary myxoid chondrosarcoma of the bone (subcutaneously implanted). |
CAR T cell study 4 (PSCA-8t28BBZ; post-infusion) / CAR T cell study 4 (PSCA-8t28BBZ; pre-infusion)
Relative Expression (log2-ratio):-3.363861Number of Samples:3 / 3
| Experimental | CAR T cell study 4 (PSCA-8t28BBZ; post-infusion) |
| CD8+ T cells transduced with PSCA-8t28BBZ (third generation CAR) and isolated 30 days after adoptive transfer into mice bearing HPAC-derived pancreatic tumor. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors PSCA-8t28BBZ. Cells were cultured for 2 weeks in presence of IL-2 and then transfered into 4-5-week-old male NSG mice. Subcutaneous xenografts were generated by injection of HPAC cells. Once tumors became palpable, mice were treated with CD8+ T cells expressing PSCA-8t28BBZ. Untransduced CD4+ cells from the same donor were given to each mouse for cytokine support. Spleen-resident human CD8+ T cells were isolated 30 days later using the CD8 MicroBeads (post-infusion samples). | |
| Control | CAR T cell study 4 (PSCA-8t28BBZ; pre-infusion) |
| Primary human CD8+ T cells stimulated ex vivo and transduced to express PSCA-8t28BBZ (third generation CAR). Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-8t28BBZ. Cells were cultured for 2 weeks in presence of IL-2, until collection of samples (pre-infusion samples). |
PBDE study 1 (2-OH-BDE85) / vehicle (DMSO) treated H295R cell sample
Relative Expression (log2-ratio):3.2679758Number of Samples:3 / 3
| Experimental | PBDE study 1 (2-OH-BDE85) |
| H295R adrenocortical carcinoma cells treated for 24 hours with 10µM of a hydroxylated form of the brominated flame retardant 2-OH-BDE85 dissolved in 0.1% dimethyl sulfoxide (DMSO). ATC code:--- | |
| Control | vehicle (DMSO) treated H295R cell sample |
| H295R adrenocortical carcinoma cells grown for 24 hours with 0.1% dimethyl sulfoxide (DMSO). |
glioma study 17 (astrocytoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)
Relative Expression (log2-ratio):3.2429771Number of Samples:3 / 3
| Experimental | glioma study 17 (astrocytoma; A2B5+) |
| Oligodendrocyte progenitor cells (OPC) isolated from low grade astrocytoma (grade II). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 36 ± 7 years old. | |
| Control | non-tumor oligodendrocyte progenitor cell sample (cortex) |
| Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. |
PBDE study 1 (2-OH-BDE47) / vehicle (DMSO) treated H295R cell sample
Relative Expression (log2-ratio):3.1413507Number of Samples:3 / 3
| Experimental | PBDE study 1 (2-OH-BDE47) |
| H295R adrenocortical carcinoma cells treated for 24 hours with 10µM of a hydroxylated form of the brominated flame retardant 2-OH-BDE47 dissolved in 0.1% dimethyl sulfoxide (DMSO). ATC code:--- | |
| Control | vehicle (DMSO) treated H295R cell sample |
| H295R adrenocortical carcinoma cells grown for 24 hours with 0.1% dimethyl sulfoxide (DMSO). |
PIK-75 study 1 / vehicle (solvent) treated H69 cell sample
Relative Expression (log2-ratio):3.1054106Number of Samples:3 / 3
| Experimental | PIK-75 study 1 |
| H69 cells (small cell lung cancer) treated with PIK-75, a small molecule affecting PIK3CA (Phodphoinositide-3-kinase catalytic subunit alpha: p110-α) ATC code:--- | |
| Control | vehicle (solvent) treated H69 cell sample |
| H69 cells (small cell lung cancer) grown in growth medium with solvent. |
CAR T cell study 4 (GFP; post-infusion) / CAR T cell study 4 (GFP; pre-infusion)
Relative Expression (log2-ratio):-3.0524654Number of Samples:3 / 3
| Experimental | CAR T cell study 4 (GFP; post-infusion) |
| CD8+ T cells transduced with GFP and isolated 30 days after adoptive transfer into mice bearing HPAC-derived pancreatic tumor. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding GFP as a control. Cells were cultured for 2 weeks in presence of IL-2 and then transfered into 4-5-week-old male NSG mice. Subcutaneous xenografts were generated by injection of HPAC cells. Once tumors became palpable, mice were treated with CD8+ T cells expressing GFP (control group). Untransduced CD4+ cells from the same donor were given to each mouse for cytokine support. Spleen-resident human CD8+ T cells were isolated 30 days later using the CD8 MicroBeads (post-infusion samples). | |
| Control | CAR T cell study 4 (GFP; pre-infusion) |
| Primary human CD8+ T cells stimulated ex vivo and transduced to express GFP. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding GFP as a control. Cells were cultured for 2 weeks in presence of IL-2, until collection of samples (pre-infusion samples). |
TGX-221 study 2 / PIK-75 study 1
Relative Expression (log2-ratio):-2.884962Number of Samples:3 / 3
| Experimental | TGX-221 study 2 |
| H69 cells (small cell lung cancer) treated with TGX-221, a small molecule affecting PIK3CB (Phodphoinositide-3-kinase catalytic subunit beta: p110-ß) ATC code:--- | |
| Control | PIK-75 study 1 |
| H69 cells (small cell lung cancer) treated with PIK-75, a small molecule affecting PIK3CA (Phodphoinositide-3-kinase catalytic subunit alpha: p110-α) ATC code:--- |